tiprankstipranks
Bioxyne Limited Hits Growth Milestone in 2024
Company Announcements

Bioxyne Limited Hits Growth Milestone in 2024

Bioxyne Limited (AU:BXN) has released an update.

Don't Miss our Black Friday Offers:

Bioxyne Limited reported a strong financial quarter with $3.1 million in revenue, marking a significant recovery and a 25% annual increase to $9.43 million after overcoming previous delays in drug control permitting. The company’s subsidiary Breathe Life Sciences achieved record revenues, and Bioxyne signed a collaboration agreement with Cy Biopharma AG for developing new psilocybin therapies. They also anticipate becoming cash flow positive in the next fiscal year thanks to recent cost-saving measures and the establishment of a new Good Manufacturing Practice facility.

For further insights into AU:BXN stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App